We have located links that may give you full text access.
Improvement of Hypothalamic Hamartoma-related Psychiatric Disorder After Stereotactic Laser Ablation: Case Report and Review of the Literature.
World Neurosurgery 2018 November 25
BACKGROUND: Hypothalamic hamartomas (HHs) are non-neoplastic congenital malformations associated with refractory epilepsy and behavioral disorders. Improvement in behavioral functioning following resection of HHs has been reported. Stereotactic laser ablation (SLA), a minimally invasive technique, has been used for the treatment of HH-related epilepsy. We report the case of child with a HH, gelastic seizures, and severe psychiatric dysfunction who was successfully treated via SLA therapy.
CASE DESCRIPTION: The patient was an 11-year-old female with history of central hypothyroidism, precocious puberty, and localization-related epilepsy thought to be secondary to a HH. She had a significant psychiatric history including Attention-Deficit/Hyperactivity Disorder (ADHD), depressed mood, impulsivity, threatening behavior, and suicidal ideation requiring management with dexmethylphenidate, bupropion, and aripiprazole. Seizure onset occurred at age 7 and her semiology included nighttime hypermotor seizures and uncontrollable laughing spells thought to be gelastic seizures. Her hypermotor seizures were successfully managed with oxcabazepine monotherapy but she continued to have several weekly laughing spells and self-harming behavior. Her HH was successfully treated via SLA. Post-operatively, she remained neurologically intact and was discharged the next day. At her 6-month follow-up, she had a markedly improved affect and general mood. At 3 years post-procedure, she remains seizure-free and has been weaned off her antiepileptic and antipsychotic medications.
CONCLUSIONS: Severe behavioral dysfunction in the setting of a HH may constitute an indication for surgical intervention. The outcome of this case suggests there may be a role for SLA in the management of HH-related psychiatric dysfunction, even in patients with good seizure control.
CASE DESCRIPTION: The patient was an 11-year-old female with history of central hypothyroidism, precocious puberty, and localization-related epilepsy thought to be secondary to a HH. She had a significant psychiatric history including Attention-Deficit/Hyperactivity Disorder (ADHD), depressed mood, impulsivity, threatening behavior, and suicidal ideation requiring management with dexmethylphenidate, bupropion, and aripiprazole. Seizure onset occurred at age 7 and her semiology included nighttime hypermotor seizures and uncontrollable laughing spells thought to be gelastic seizures. Her hypermotor seizures were successfully managed with oxcabazepine monotherapy but she continued to have several weekly laughing spells and self-harming behavior. Her HH was successfully treated via SLA. Post-operatively, she remained neurologically intact and was discharged the next day. At her 6-month follow-up, she had a markedly improved affect and general mood. At 3 years post-procedure, she remains seizure-free and has been weaned off her antiepileptic and antipsychotic medications.
CONCLUSIONS: Severe behavioral dysfunction in the setting of a HH may constitute an indication for surgical intervention. The outcome of this case suggests there may be a role for SLA in the management of HH-related psychiatric dysfunction, even in patients with good seizure control.
Full text links
Related Resources
Trending Papers
Heart failure with preserved ejection fraction: diagnosis, risk assessment, and treatment.Clinical Research in Cardiology : Official Journal of the German Cardiac Society 2024 April 12
Proximal versus distal diuretics in congestive heart failure.Nephrology, Dialysis, Transplantation 2024 Februrary 30
Efficacy and safety of pharmacotherapy in chronic insomnia: A review of clinical guidelines and case reports.Mental Health Clinician 2023 October
World Health Organization and International Consensus Classification of eosinophilic disorders: 2024 update on diagnosis, risk stratification, and management.American Journal of Hematology 2024 March 30
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app